Observations from preclinical and early clinical literature.

• Tissue Repair: Both peptides demonstrate wound-healing, tendon-repair, and anti-inflammatory properties in animal models.
• Gastrointestinal Support: BPC-157 shows gastroprotective and ulcer-healing effects in preclinical studies.
• Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose up to ~20 mg/kg); TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg.
• Possible Side Effects: Occasional mild injection-site reactions (redness, itching); rare reports of transient dizziness or nausea; long-term human safety data remain limited.

TB-500 (Thymosin β4) is a naturally occurring peptide that regulates actin polymerization, promotes cell migration, reduces inflammation, and supports wound healing and tissue regeneration.